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Identity 
Other names: CD146, METCAM, MUC18, Gicerin 




Human METCAM (huMETCAM), a CAM in the 
immunoglobulin-like gene superfamily, is an integral 
membrane glycoprotein. Alternative names for 
METCAM are MUC18 (Lehmann et al., 1987), CD146 
(Anfosso et al., 2001), MCAM (Xie et al., 1997), 
MelCAM (Shih et al., 1994a), A32 (Shih et al., 1994b), 
and S-endo 1 (Bardin et al., 1996).  
To avoid confusion with mucins and to reflect its 
biological functions, we have renamed MUC18 as 
METCAM (metastasis CAM), which means an 
immunoglobulin-like CAM that affects or regulates 
metastasis, (Wu, 2005). METCAM/MUC18 gene is 
located on human chromosome 11q23.3. 
Transcription 
The major transcript of the gene in most human 
epithelial cancer cell lines is about 3,3 kb (Wu et al., 
2001a).  
A distinct short form resulting from alternative splicing 
of the gene of gicerin, the chicken homolog of 
METCAM, has been found (Taira et al., 1995).  
Though the expression of a short form of METCAM 
has been briefly mentioned in human melanoma cells 
(Lehmann et al., 1987), its function is not known si ce 
it is expressed at a much lower level than the major 
form in various cancer cell lines (Wu, unpublished 
observation). Interestingly, a truncated form with a 
deletion in some portion of the cytoplasmic domain has
been found in a prostate cancer specimen X9479, a cell 
line derived from specimens of nasopharyngeal 
carcinomas and other cancers (Wu, unpublished 
observations).  
Further systematic search for the function of this m nor 
form should be carried out. 
Pseudogene 
METCAM/MUC18 may not have a pseudogene. 
Protein 
Note 
Human METCAM/MUC18 cDNA encodes 646 amino 
acids, about 115-150 kDa protein. 
Description 
The huMETCAM has 646 amino acids that include a 
N-terminal extra-cellular domain of 558 amino acids, 
which has 28 amino acids characteristics of a signal 
peptide sequence at its N-terminus, a transmembrane 
domain of 24 amino acids (amino acids 559-583), and a 
cytoplasmic domain of 64 amino acids at the C-
terminus. HuMETCAM has eight putative N-
glycosylation sites (Asn-X-Ser/Thr), of which six are 
conserved, and are heavily glycosylated and sialylated 
resulting in an apparent molecular weight of 113000-
150000.The extra-cellular domain of the protein 
comprises five immunoglobulin-like domains (V-V-
C2-C2-C2) (Lehmann et al., 1987; Wu et al., 2001a; 
Wu, 2005) and an X domain (Wu et al., 2001a; Wu, 
2005). 
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HuMETCAM protein structure. SP stands for signal peptide sequence, V1, V2, C2, C2', C2'' for five Ig-like domains (each held by a 
disulfide bond) and X for one domain (without any disulfide bond) in the extracellular region, and TM for transmembrane domain. P 
stands for five potential phosphorylation sites (one for PKA, three for PKC, and one for CK2) in the cytoplasmic tail. The six conserved N-
glycosylation sites are shown as wiggled lines in the extracellular domains of V1, between C2' and C2'', C2'', and X. 
The cytoplasmic tail contains peptide sequences that 
will potentially be phosphorylated by protein kinase A 
(PKA), protein kinase C (PKC), and casein kinase 2 
(CK 2) (Lehmann et al., 1987; Wu et al., 2001a; Wu, 
2005). My lab has also cloned and sequenced the 
mouse METCAM (moMETCAM) cDNA, which 
contains 648 amino acids with a 76,2% identity with 
huMETCAM, suggesting that moMETCAM is likely to 
have biochemical properties and biological functions 
similar to the human counter part (Yang et al., 2001; 
Wu, 2005).  
The structure of the huMETCAM protein is depicted in 
figure above, suggesting that METCAM, similar to 
most CAMs, plays an active role in mediating cell-cll 
and cell-extracellular interactions, crosstalk with many 
intracellular signaling pathways, and modulating the 
social behaviors of cells (Cavallaro and Christofori, 
2004; Wu, 2005). Recent work supports an emerging 
novel function of METCAM in tumor angiogenesis and 
perhaps it plays an important role in the metastasi of 
tumor cells (Wu, 2010; Wu, 2012). 
Expression 
HuMETCAM is expressed in a limited number of 
normal tissues, such as hair follicular cells, smooth 
muscle cells, endothelial cells, cerebellum, normal 
mammary epithelial cells, basal cells of the lung, 
activated T cells, intermediate trophoblast (Shih, 1999), 
and normal nasopharyngeal epithelial cells (Lin et al., 
2012). 
Localisation 
HuMETCAM is a cytoplasmic membrane protein. 
Most of the protein is located on the cell membrane in 
normal tissues. However, increasing presence of the 
protein in the cytoplasm appears to be related to the 
higher pathological grades and malignant cancers of 
prostate and breast, and melanoma and nasopharyngeal 
carcinoma (Wu et al., 2001b). 
Function 
Similar to other cell adhesion molecules (CAMs), 
METCAM/MUC18 does not merely act as a molecular 
glue to hold together homotypic cells in a specific 
tissue or to facilitate interactions of heterotypic cells; It 
also actively governs the social behaviors of cells by 
affecting the adhesion status of cells and modulating 
cell signaling (Cavallaro and Christofori, 2004).  
It controls cell motility and invasiveness by mediating 
the remodeling of cytoskeleton (Cavallaro and 
Christofori, 2004).  
It also actively mediates the cell-to-cell and cell-to-
extracellular matrix interactions to allow cells to 
constantly respond to physiological fluctuations and to 
alter/remodel the surrounding microenvironment for 
survival (Chambers et al., 2002).  
It does so by crosstalk with cellular surface growth 
factor receptors, which interact with growth factors that 
may be secreted from stromal cells or released from 
circulation and embedded in the extracellular matrix 
(Chambers et al., 2002; Cavallaro and Christofori, 
2004).  
Thus an altered expression of METCAM/MUC18 
affects the motility and invasiveness of many epithel al 
tumor cells in vitro and metastasis in vivo (Chambers et 
al., 2002; Cavallaro and Christofori, 2004; Wu, 2005). 
METCAM/MUC18 may also play an important role in 
the favorable soil that provides a proper 
microenvironment at a suitable period to awaken the 
dormant metastatic tumor cells to enter into an 
aggressive growth phase.  
Evidence have been documented that aberrant 
expression of huMETCAM/MUC18 actually affects the 
motility and invasiveness of many tumor cells in vitro 
and metastasis in vivo.  
Thus HuMETCAM/MUC18 plays an important role in 
promoting the malignant progression of many cancer 
types (Cavallaro and Christofori, 2004; Wu, 2005). 
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Homology 
Human METCAM/MUC18 protein shares high 
homology with the mouse METCAM/MUC18 (Wu et 
al., 2001a; Yang et al., 2001) and other Ig-like CAMs, 
especially the NCAMs (Lehmann et al., 1987). 
Mutations 
Note 
Several point mutations have been found in 
huMETCAM/MUC18 protein from human cancers 




The protein is overly expressed in most (67%) 
malignant melanoma cells (Lehmann et al., 1987), and 
in most (more than 80%) pre-malignant prostate 
epithelial cells (PIN), high-grade prostatic carcinoma 
cells, and metastatic lesions (Wu et al., 2001b; Wu, 
2004). HuMETCAM is also expressed in other cancers, 
such as gestational trophoblastic tumors, 
leiomyosarcoma, angiosarcoma, haemangioma, 
Kaposi's sarcoma, schwannoma, some lung squamous 
and small cell carcinomas, some breast cancer, some 
neuroblastoma (Shih, 1999), and also nasopharyngeal 




Over-expression of huMETCAM has been shown to 
promote tumorigenesis of four breast cancer cell lines 
in athymic nude mice and perhaps the malignant 
progression of breast cancer cells (Zeng et al., 2011; 
Zeng et al., 2012). 
Prognosis 
Over-expression of huMETCAM/MUC18 has been 
implicated in a poor prognosis of breast cancer. 
Prostate cancer 
Note 
Over-expression of huMETCAM has been shown to 
promote tumorigenesis and metastasis of human 
prostate cancer LNCaP cells in athymic nude mice (Wu
et al., 2001a; Wu et al., 2001b; Wu, 2004; Wu et al., 
2004; Wu et al., 2011). 
Disease 
Human prostate cancer (Wu et al., 2001a; Wu et al., 
2001b; Wu, 2004; Wu et al., 2004; Wu et al., 2011) and
the TRAMP models (Wu et al., 2005). 
Prognosis 
Over-expression of huMETCAM/MUC18 has been 
implicated in a poor prognosis of prostate cancer (Wu 
et al., 2001a; Wu et al., 2001b, Wu, 2004). 
 
Oncogenesis 
METCAM/MUC18 promotes the oncogenesis of 
human prostate cancer cells (Wu et al., 2001a; Wu et 
al., 2001b; Wu, 2004; Wu et al., 2004; Wu et al., 2011). 
Melanoma 
Note 
Over-expression of huMETCAM has been shown to 
promote metastasis, but not the tumorigenesis, of 
human melanoma (Xie et al., 1997; Schlagbauer-Wadl 
et al., 1999) and mouse melanoma cells (Yang et al., 
2001; Wu et al., 2008) in immunodeficent nude mice. 
Prognosis 
Over-expression of huMETCAM/MUC18 has been 
implicated in a poor prognosis of melanoma (Lehmann 
et al., 1987; Shih, 1999). 
Oncogenesis 
METCAM does not appear to promote the oncogenesis 
of human and most melanoma cells (Wu et al., 2008). 
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